A Phase 3 interventional study of Entocort in Crohn's Disease, sponsored by Padagis LLC. Completed at 24 sites in 5 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-01-06.
Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.
Among the 660 studies in Crohn Disease with a site in United States, this one is the 178th largest by enrollment of the 528 interventional ones that give a count, is one of 33 that started in 2011, is one of 124 in phase 3, and was the 192nd registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:
Shattuck Labs, Inc. · Sites in United States
Ages 18–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Agomab Spain S.L.U. · Sites in United States, Serbia, United Kingdom
Ages 18+
University of Miami · Sites in United States
Ages 16–75
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
660 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 179 · Phase 3 134 · Phase 4 41
First in 1995; this study’s year is marked. 33 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 60 across the 528 interventional studies, 168 across the 128 observational. Of the 452 that completed or were terminated, 205 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
310 of 660 have an industry lead sponsor. The 10 most frequent:
Padagis LLC is the lead sponsor of 37 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Padagis LLC has 2 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
59 of the studies in Crohn Disease with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT05660746Phase 3Children's Hospital Medical Center, CincinnatiPrecise Infliximab Exposure and Pharmacodynamic Control | 2027-03-31 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
Add all 59 to your calendar (.ics) → With an account.
Among the 660 studies in Crohn Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Safety Study using Entocort EC for children with mild to moderate Crohn's Disease
A Multicenter, Open label, Non-comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Study Medication
Drug: Entocort
Entocort capsules, oral
Adverse Event
Number of patients with at least one adverse event
Time frame: 12 weeks
PCDAI
Paediatric Crohn's Disease Activity Index. Range from 0 (best) to 100 (worst).
Time frame: Baseline to 8 weeks
IMPACT 3
IMPACT 3 is a self-administered QoL form. The score ranges from 35 (poor) to 175 (best).
Time frame: Baseline to 8 weeks
123 patients were screened/enrolled, but only 108 received treatment. The other 15 did not meet the inclusion/exclusion criteria. They only appear in the disposition tables in the CSR (Tables 8 and 10) and did not "start" in the study.
| Milestone | Entocort |
|---|---|
| Started | 108 |
| Informed consent obtained | 108 |
| Completed | 91 |
| Not completed | 17 |
| Withdrew: Adverse event | 8 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Other eligibility criteria | 7 |
Number of patients with at least one adverse event
| Patients | Entocort |
|---|---|
| Adverse Event | 79 |
Paediatric Crohn's Disease Activity Index. Range from 0 (best) to 100 (worst).
| Units on a scale | Entocort |
|---|---|
| Baseline (Day1) | 19.10 ± 10.1 |
| Change after 8 weeks | -10.0 ± 10.1 |
IMPACT 3 is a self-administered QoL form. The score ranges from 35 (poor) to 175 (best).
| Units on a scale | Entocort |
|---|---|
| Baseline (Day 1) | 132.1 ± 18.8 |
| Change after 8 weeks | 7.8 ± 13.3 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Entocort | — | 8/108 (7.4%) | 78/108 (72.2%) |
| Event | Entocort |
|---|---|
| Crohn's diseaseGastrointestinal disorders | 4/108 |
| Diarrhoea haemorrhagicGastrointestinal disorders | 1/108 |
| Small intestinal obstructionGastrointestinal disorders | 1/108 |
| HypokalaemiaMetabolism and nutrition disorders | 1/108 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/108 |
| Erythema nodosumSkin and subcutaneous tissue disorders | 1/108 |
| Event | Entocort |
|---|---|
| Increased appetiteMetabolism and nutrition disorders | 17/108 |
| Abdominal painGastrointestinal disorders | 16/108 |
| AcneSkin and subcutaneous tissue disorders | 15/108 |
| IrritabilityPsychiatric disorders | 14/108 |
| CushingoidEndocrine disorders | 13/108 |
| HeadacheNervous system disorders | 9/108 |
| Crohn's diseaseGastrointestinal disorders | 7/108 |
| NauseaGastrointestinal disorders | 6/108 |
| Decreased appetiteMetabolism and nutrition disorders | 6/108 |
| InsomniaPsychiatric disorders | 6/108 |
| Age, Continuous(Years) | Entocort |
|---|---|
| Mean | 13.7 ± 2.41 |
| Age, Customized(Participants) | Entocort |
|---|---|
| =<8 Yrs | 5 |
| >8 Yrs | 103 |
| Sex: Female, Male(Participants) | Entocort |
|---|---|
| Female | 51 |
| Male | 57 |
| Race/Ethnicity, Customized(Participants) | Entocort |
|---|---|
| Asian | 1 |
| Black Or African American | 4 |
| Other | 3 |
| White | 100 |
The record gives a start of Nov 2011, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide